These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

63 related articles for article (PubMed ID: 6772954)

  • 1. Cost effectiveness of therapeutic and prophylactic leukocyte transfusion.
    Glassman AB
    N Engl J Med; 1980 Sep; 303(13):759-60. PubMed ID: 6772954
    [No Abstract]   [Full Text] [Related]  

  • 2. The cost effectiveness of therapeutic and prophylactic leukocyte transfusion.
    Rosenshein MS; Farewell VT; Price TH; Larson EB; Dale DC
    N Engl J Med; 1980 May; 302(19):1058-62. PubMed ID: 6767978
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost effectiveness of therapeutic and prophylactic leukocyte transfusion.
    Clift RA; Buckner CD
    N Engl J Med; 1980 Sep; 303(13):760. PubMed ID: 6772955
    [No Abstract]   [Full Text] [Related]  

  • 4. Leukocyte-reduced blood components: patient benefits and practical applications.
    Higgins VL
    Oncol Nurs Forum; 1996 May; 23(4):659-67. PubMed ID: 8735324
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evidence-based recommendations for the use of WBC-reduced cellular blood components.
    Ratko TA; Cummings JP; Oberman HA; Crookston KP; DeChristopher PJ; Eastlund DT; Godwin JE; Sacher RA; Yawn DH; Matuszewski KA;
    Transfusion; 2001 Oct; 41(10):1310-9. PubMed ID: 11606834
    [No Abstract]   [Full Text] [Related]  

  • 6. Implementation of peripheral blood CD34 analyses to initiate leukapheresis: marked reduction in resource utilization.
    Meehan KR; Hill JM; Patchett L; Webber SM; Wu J; Ely P; Szczepiorkowski ZM
    Transfusion; 2006 Apr; 46(4):523-9. PubMed ID: 16584427
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-effectiveness of a potential prophylactic Helicobacter pylori vaccine in the United States.
    Rupnow MF; Chang AH; Shachter RD; Owens DK; Parsonnet J
    J Infect Dis; 2009 Oct; 200(8):1311-7. PubMed ID: 19751153
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment cost of ulcerative colitis is apheresis with Adacolumn cost-effective?
    Panés J; Guilera M; Ginard D; Hinojosa J; González-Carro P; González-Lara V; Varea V; Domènech E; Badia X
    Dig Liver Dis; 2007 Jul; 39(7):617-25. PubMed ID: 17531555
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Current status of leukocyte and platelet administration in cancer therapy.
    Walker EM; Cannon A; Mitchum EN
    Ann Clin Lab Sci; 1983; 13(6):453-73. PubMed ID: 6197928
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Assessing cost effectiveness of empirical and prophylactic therapy for managing leptospirosis outbreaks.
    Galloway RL; Levett PN; Tumeh JW; Flowers CR
    Epidemiol Infect; 2009 Sep; 137(9):1323-32. PubMed ID: 19161641
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Leukocyte reduction of cellular blood components. Effectiveness, benefits, quality control, and costs.
    Lane TA
    Arch Pathol Lab Med; 1994 Apr; 118(4):392-404. PubMed ID: 8166589
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost benefit and cost effectiveness analysis: a bibliography for pharmacists.
    Lunik MC; Segal R
    Hosp Pharm; 1986 Nov; 21(11):1072-5. PubMed ID: 10311748
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-effectiveness of therapeutic hypothermia after cardiac arrest.
    Merchant RM; Becker LB; Abella BS; Asch DA; Groeneveld PW
    Circ Cardiovasc Qual Outcomes; 2009 Sep; 2(5):421-8. PubMed ID: 20031872
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anemia therapy: individual benefit and societal cost.
    Denton TA; Diamond GA; Matloff JM; Gray RJ
    Semin Oncol; 1994 Apr; 21(2 Suppl 3):29-35. PubMed ID: 8202723
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-benefit and cost-effectiveness analysis.
    Hosp Cost Manag Account; 1993 Feb; 4(11):1-4. PubMed ID: 10123516
    [No Abstract]   [Full Text] [Related]  

  • 16. Cost effectiveness of rabies post exposure prophylaxis in the United States.
    Dhankhar P; Vaidya SA; Fishbien DB; Meltzer MI
    Vaccine; 2008 Aug; 26(33):4251-5. PubMed ID: 18599167
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Understanding cost-effectiveness in the ICU.
    Zilberberg MD
    Semin Respir Crit Care Med; 2010 Feb; 31(1):13-8. PubMed ID: 20101543
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Estimated effectiveness and cost-effectiveness of federally funded prevention efforts on gonorrhea rates in the United States, 1971-2003, under various assumptions about the impact of prevention funding.
    Chesson HW
    Sex Transm Dis; 2006 Oct; 33(10 Suppl):S140-4. PubMed ID: 16505737
    [TBL] [Abstract][Full Text] [Related]  

  • 19. When is a cost-effectiveness claim valid? How much should the FDA care?
    Luce BR; Hillman AL
    Am J Manag Care; 1997 Nov; 3(11):1660-6. PubMed ID: 10178464
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Proposed drug-drug cost effectiveness methodology.
    Gagnon JP; Osterhaus JT
    Drug Intell Clin Pharm; 1987 Feb; 21(2):211-6. PubMed ID: 3103997
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.